Why is Tenax Therapeutics facing a securities class action lawsuit?

Investors allege Tenax Therapeutics made misleading statements about the efficacy of TNX-103 and overstated its clinical, regulatory, and commercial prospects before the drug failed key Phase 3 trial endpoints.

What are the main allegations against Tenax Therapeutics?

The complaint alleges Tenax overstated TNX-103's effectiveness and prospects while making materially misleading statements about the drug's potential clinical and commercial success.

What is TNX-103, and why is it involved in the Tenax Therapeutics lawsuit?

TNX-103 is an investigational drug developed by Tenax Therapeutics. Plaintiffs allege the Company misrepresented its effectiveness and potential for clinical, regulatory, and commercial success.

What happened in Tenax Therapeutics' Phase 3 LEVEL clinical trial?

On August 10, 2026, Tenax announced that TNX-103 failed to meet the trial's primary endpoint measuring 6-minute walk distance and its key secondary endpoint assessing patient-reported symptoms.

Why did Tenax Therapeutics stock fall on August 10, 2026?

Following disappointing Phase 3 LEVEL trial results, Tenax shares declined approximately $12.06, or 89.77%, to close at $1.38 per share on August 10, 2026.

What was the primary endpoint of the Tenax Therapeutics Phase 3 LEVEL trial?

The primary endpoint measured improvement in 6-minute walk distance compared with placebo. Tenax reported that TNX-103 failed to demonstrate the required improvement.

What secondary endpoint did TNX-103 fail in the Phase 3 LEVEL trial?

TNX-103 failed its key secondary endpoint measuring improvement in the Kansas City Cardiomyopathy Questionnaire total symptom score, which assesses patient-reported heart failure symptoms.

What are investors alleging about TNX-103's clinical effectiveness?

Plaintiffs allege TNX-103 was less effective than Tenax had represented, resulting in misleading expectations regarding the drug's clinical performance and potential regulatory approval.

How could the failed Phase 3 LEVEL trial affect TNX-103's future?

Failure to meet key Phase 3 endpoints may complicate TNX-103's regulatory approval process, future clinical development, and potential commercialization.

What are investors alleging about Tenax Therapeutics' public statements?

The complaint alleges Tenax made materially false or misleading statements about TNX-103's effectiveness and overstated the drug's clinical, regulatory, and commercial prospects.

Who may be eligible to participate in the Tenax Therapeutics securities class action?

Investors who purchased or acquired Tenax Therapeutics (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026 may be eligible if they suffered losses.

What is the lead plaintiff deadline in the Tenax Therapeutics securities class action?

Eligible Tenax Therapeutics investors seeking appointment as lead plaintiff must file a motion with the court by December 28, 2026.

What is a securities class action lawsuit?

A securities class action allows investors to collectively pursue claims involving alleged material misstatements, misleading disclosures, or omissions concerning publicly traded securities.

What is a lead plaintiff in a securities class action lawsuit?

A lead plaintiff is an investor appointed by the court to represent the proposed class and help oversee the litigation on behalf of class members.

Do Tenax Therapeutics investors need to become lead plaintiff to participate in a potential recovery?

No. Eligible Tenax Therapeutics investors generally do not need to serve as lead plaintiff to participate in a potential settlement or other class-wide recovery.

Tenax Therapeutics, Inc. - Faruqi & Faruqi LLP

Tenax Therapeutics, Inc.

Join Action

Case Details

Filed On: October 27, 2026

Ticker TENX

Class Period 11/13/2023 - 08/07/2026

Lead Plaintiff Deadline 12/28/2026

Days Left to Seek Lead Plaintiff

If you are a Tenax Therapeutics investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Tenax between November 13, 2023 and August 7, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tenax Therapeutics, Inc. (“Tenax” or the “Company”) (NASDAQ: TENX) and reminds investors of the December 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) TNX-103 was less effective than Defendants had led investors to believe; (2) accordingly, TNX-103’s overall clinical, regulatory, and commercial prospects were overstated; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Lead Plaintiff Deadline: December 28, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).

Or submit your information below to learn about your rights.

Join Action

Tenax Therapeutics, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify